Abbott’s Eterna spinal cord stimulation system given FDA approval
December 20, 2022Medical Communications
US-based Abbott Laboratories has announced that their Eterna spinal cord stimulation (SCS) system has been given approval by the FDA. …
Unison boss states Government has “adamantly refused” to engage in a “proper discussion” on pay ahead of Wednesday’s ambulance strikes
December 19, 2022Medical Communications
Unison general secretary Christina McAnea has said that Wednesday’s ambulance strikes will go ahead without a “very firm commitment” on …
FDA approves first gene therapy to treat patients with high-risk, non-muscle-invasive bladder cancer
December 19, 2022Medical Communications
The FDA has approved Adstiladrin (scientific name nadofaragene firadenovec-vncg) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive …
New study shares effectiveness of asthma drug compared to standard of care
December 19, 2022Research and Development
The University of Plymouth has co-authored a new study, published in The Lancet, which shows how an asthma drug, commercially …
Targeted imaging agent for lung cancer surgery approved by FDA
December 19, 2022Research and Development
The FDA has approved Cytalux (pafolacianine) to be used in lung cancer surgery: the targeted imaging agent binds to cancerous …
Psoriasis community comes together and calls for collective action to help improve the lives of people with psoriasis
December 19, 2022Business Services
Slough, UK, 15 December 2022 – UCB, a global biopharmaceutical company, has announced results from the Epicensus programme, published in …
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 19, 2022Business Services
Tokyo, Japan and Cambridge, UK, 16 December 2022 – Sosei Group Corporation (“the Company”; TSE: 4565) announces it has entered …
Alchemab Therapeutics and Medicines Discovery Catapult awarded £1.7 million grant from Innovate UK to accelerate development of disease-modifying therapy for Huntington’s Disease
December 19, 2022Business Services
Cambridge, UK. December 16 2022 – Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today …
CDC provides $12.5m grant to study real-world effectiveness of vaccines
December 16, 2022Research and Development
The Center for Disease Control and Prevention (CDC) has given researchers at Washington University School of Medicine in St Louis, …
New blood test appears to detect hidden cancer
December 16, 2022Research and Development
Biotech company Guardant Health has announced that its blood test-based cancer screening technique appears to be effective: the liquid biopsy …
Anumana and Pfizer team up on AI-enabled ECG algorithm for detection of cardiovascular disease
December 16, 2022Medical Communications
Anumana, an AI-driven health technology firm, has signed a multi-year deal with Pfizer in order to develop an AI electrocardiogram …
Eli Lilly and Sosei Heptares enter into multi-target collaboration and license agreement for diabetes and metabolic diseases
December 16, 2022Medical Communications
Japan-based Sosei Heptares announced that it has joined forces with UK global biopharma company Eli Lilly to discover, develop and …
Johnson & Johnson and Merck’s Ebola vaccines show lasting protection
December 15, 2022Medical Communications
The two Ebola vaccines developed by Johnson & Johnson and Merck appeared successful according to two studies: they both produced …
European Commission approves Dupixent® as the first and only targeted medicine for prurigo nodularis
December 15, 2022Medical Communications
Regeneron Pharmaceuticals and Sanofi have announced that the European Commission (EC) has expanded the marketing authorisation for Dupixent® (dupilumab) in …
LumiraDx receives $14m in funding for point-of-care TB test
December 15, 2022Medical Communications
UK-based point-of-care diagnostics company LumiraDx has been given $14m in grants from the Bill & Melinda Gates Foundation to support …
New drug application for AstraZeneca’s Lynparza given more time by FDA
December 15, 2022Medical Communications
AstraZeneca and its US collaborator, Merck, have announced that the FDA is allowing more time for the review of the …
FlyPharma Conference Middle East: New location announced
December 14, 2022Business Services
FlyPharma Conferences are pleased to announce an exciting new addition to its event portfolio: FlyPharma Middle East. Taking place in …
David Brocklehurst
December 14, 2022Business Services
London, UK, 12 December 2022 – AstraZeneca UK announces the appointment of David Brocklehurst as Head of Oncology in the …
Merck and Moderna’s mRNA cancer vaccine is successful in efficacy trial
December 14, 2022Research and Development
Merck & Co and Moderna have partnered to utilise the mRNA technology used to combat COVID-19, however this time the …
ClearPoint recruits first patient in laser therapy study to treat Glioblastoma
December 14, 2022Research and Development
California, US-based ClearPoint Neuro has recruited the first patient in a clinical trial which will use ClearPoint’s Prism Neuro Laser …
